Search

Displaying results 5031 - 5040 of 8974 in total
  1. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.

  2. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

  3. Drug

    Haemagglutinin-strain B

    go.drugbank.com/drugs/DB15482
    ApprovedInvestigational

    Mixtures: Influvac Suspension for Injection
  4. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  5. Drug

    Asiatic acid

    go.drugbank.com/drugs/DB14054
    Investigational

    From Centella asiatica and other plants; shows a variety of bioactivities.

    Mixtures: liquid Wart Corn Callus Remover
  6. Indication

    Gaucher Disease, Type 1

    go.drugbank.com/conditions/DBCOND0035324
    Drugs: Eliglustat · Imiglucerase · Taliglucerase alfa · Velaglucerase alfa
    Synonyms: Gaucher Disease, Non-Neuronopathic Form
  7. Drug

    Betaxolol

    go.drugbank.com/drugs/DB00195
    ApprovedInvestigational

    A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

    Categories: Antihypertensive Agents Indicated for Hypertension
  8. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. … Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

  9. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury. … Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease.

  10. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.